CJC-1295
Clinical reviewer: Jacob Moore, MD · Last checked September 16, 2026
What is CJC-1295?
CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH) studied in two 2006 randomized trials for its ability to raise growth hormone and IGF-1 levels. It is not FDA-approved. Its 503A bulks-list nomination was withdrawn after FDA identified serious adverse events, and it is not eligible for compounding under section 503A.
What does trial data show about CJC-1295?
A 2006 study ran two randomized, placebo-controlled, ascending-dose trials of CJC-1295 in healthy adults aged 21 to 61. A single subcutaneous injection raised mean plasma growth hormone 2- to 10-fold for six days or more, and IGF-I 1.5- to 3-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days. The study authors reported no serious adverse reactions in those trials [1].
What is CJC-1295's FDA status now?
FDA's Category 2 list, current as of April 22, 2026, shows CJC-1295's nomination was withdrawn after the agency identified serious adverse events, including increased heart rate and a systemic vasodilatory reaction, and noted available clinical data are limited [2]. It also does not appear anywhere in FDA's May 14, 2026 categories document [3]. Because it has no USP monograph, is not part of an approved drug, and is not on the 503A bulks list, no 503A route currently applies [4].
Related terms
Sources
- Teichman SL et al. Prolonged Stimulation of Growth Hormone and IGF-I Secretion by CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog. J Clin Endocrinol Metab, 2006.
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2), current as of April 22, 2026
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026)
- FDA — Bulk Drug Substances Used in Compounding Under Section 503A
This entry is for education and is not medical advice. Talk with a licensed clinician about your own situation before starting, stopping, or changing any treatment.
